10.57647/ijnd.2026.1703.17

Engineering PVA-Based Nanofibrous Mats Containing Pramipexole with Anti-Parkinsonian Effects: Fabrication, Characterization, and Pharmacological Study

XML PDF
  • Maryam Ghaffarimoghadam1,
  • Mitra Baghali2,
  • Majid Motaghinejad3,
  • Hakimeh Ziyadi*4,
  • Danial Sadri1,
  1. Pharmaceutical Sciences Research Center, TeMS.C., Islamic Azad University, Tehran, Iran
  2. Research School of Chemistry & Applied Biomedical Sciences, Tomsk Polytechnic University, Lenin Avenue 43, 63400, Tomsk, Russian Federation
  3. Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
  4. Department of Organic Chemistry, TeMS.C., Islamic Azad University, Tehran, Iran

Received: 2025-09-18

Revised: 2026-03-14

Accepted: 2026-04-29

Published in Issue 2026-07-10

Published Online: 2026-06-09

Copyright (c) 2025 Maryam Ghaffarimoghadam, Mitra Baghali, Majid Motaghinejad, Hakimeh Ziyadi, Danial Sadri (Author)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Ghaffarimoghadam, M., Baghali, M., Motaghinejad, M., Ziyadi, H., & Sadri, D. (2026). Engineering PVA-Based Nanofibrous Mats Containing Pramipexole with Anti-Parkinsonian Effects: Fabrication, Characterization, and Pharmacological Study. International Journal of Nano Dimension, 17(3). https://doi.org/10.57647/ijnd.2026.1703.17
Crossref
Scopus
Google Scholar
Europe PMC

PDF views: 32

Abstract

Parkinson’s disease is a progressive neurodegenerative disorder that requires long-term pharmacotherapy; however, conventional oral administration of pramipexole is associated with fluctuating plasma levels and systemic side effects. In this study, a novel electrospun PVA-based nanofibrous transdermal patch containing pramipexole was developed to enable controlled drug delivery and improved therapeutic efficacy. Pramipexole-loaded PVA and PVA/PVP nanofibers were fabricated via electrospinning and subsequently cross-linked using glutaraldehyde vapor. The nanofibrous mats were characterized in terms of morphology, wettability, rheological behavior, drug release kinetics, and in vivo neuroprotective performance. Smooth and bead-free nanofibers were obtained, confirming suitable solution viscosity and electrospinnability. Water contact angle measurements demonstrated hydrophilic behavior, with contact angles of 33° for PVA, 71° for PVA/PVP, and 43° for cross-linked PVA/PVP/pramipexole nanofibers, indicating tunable surface wettability. In vitro release studies revealed an initial burst release of approximately 43% and 32% of pramipexole within 30 min for PVA and PVA/PVP nanofibers, respectively, followed by sustained release reaching ~52% and ~49% after 24 h. In contrast, cross-linked nanofibers exhibited significantly slower and more controlled drug release due to reduced polymer network permeability. Histopathological analysis of the substantia nigra region in a paraquat-induced Parkinson’s disease model demonstrated a marked reduction in neuronal degeneration in both systemic and transdermal pramipexole-treated groups compared to untreated animals.

Keywords

  • Behavioral assessments,
  • Nanofiber; Parkinson,
  • Poly Vinyl Alcohol (PVA),
  • Polyvinylpyrrolidone (PVP),
  • Pramipexole,
  • Transdermal mat
PDF

References

  1. Dzulkharnien N. S. F., Rohani R., (2022) A review on current designation of metallic nanocomposite hydrogel in biomedical applications, Nanomaterials. 12:1629. https://doi.org/10.3390/nano12101629
  2. Salvador-Morales C., Grodzinski P., (2022) Nanotechnology tools enabling biological discovery, ACS Nano. 16:5062–84. https://doi.org/10.1021/acsnano.1c10635
  3. Chausali N., Saxena J., Prasad R., (2022) Recent trends in nanotechnology applications of bio-based packaging, J. Agric. Food Res. 7:100257. https://doi.org/10.1016/j.jafr.2021.100257
  4. Dhanjal D.S., Mehra P., Bhardwaj S., Singh R., Sharma P., Nepovimova E., et al. (2022) Mycology-nanotechnology interface: applications in medicine and cosmetology, Int. J. Nanomed. 17:2505–33. https://doi.org/10.2147/IJN.S363282
  5. Pourjafari M., Ghane M., Kaboosi H., Sadeghi B., Rezaei A., (2022) Antibacterial Properties of Ag–Cu Alloy Nanoparticles Against Multidrug-Resistant Pseudomonas aeruginosa Through Inhibition of Quorum Sensing Pathway and Virulence-Related Genes, Journal of Biomedical Nanotechnology. 18: 1196-1204. https://doi.org/10.1166/jbn.2022.3331
  6. Torres-Martínez E.J., Cornejo Bravo J.M., Serrano Medina A., P´erez Gonz´alez G.L., Villarreal G´omez L.J., (2018) A summary of electrospun nanofibers as drug delivery system: Drugs loaded and biopolymers used as matrices, Curr. Drug Delivery. 15:1360–74. https://doi.org/10.2174/1567201815666180723114326
  7. Baghali M., Ziyadi H., Faridi-Majidi R., (2022) Fabrication and characterization of core–shell TiO2 containing nanofbers of PCL zein by coaxial electrospinning method as an erythromycin drug carrier, polymer bulletin. 79:1729–49. https://doi.org/10.1007/s00289-021-03591-3
  8. Suri S.S., Fenniri H., Singh B., (2007) Nanotechnology-based drug delivery systems, J. Occup. Med. Toxicol. 2. https://doi.org/10.1186/1745-6673-2-16
  9. Sch¨atzlein A.G., (2006) Delivering cancer stem cell therapies–A role for nanomedicines Eur. J. Cancer. 42:1309–15 https://doi.org/10.1016/j.ejca.2006.01.044
  10. Rahmani A., Nadri S., Kazemi H.S., Mortazavi Y., Sojoodi M., (2019) Conductive electrospun scaffolds with electrical stimulation for neural differentiation of conjunctiva mesenchymal stem cells, Artif. Organs. 43:780–90. https://doi.org/10.1111/aor.13425
  11. Zahmatkeshan M., Adel M., Bahrami S., Esmaeili F., Rezayat S.M., Saeedi Y., et al. (2018) Polymer based nanofibers: preparation, fabrication, and applications. In: Springer eBooks. 2018. p. 1–47.
  12. Amna R., Ali K., Malik M.I., Shamsah S.I., (2020) A Brief Review of Electrospinning of Polymer Nanofibers: History and Main Applications, J. New Mater. Electrochem. Syst. 23:151–63. http://dx.doi.org/10.14447/jnmes.v23i3.a01
  13. Barhoum A., Pal K., Rahier H., Uludag H., Kim I.S., Bechelanya M., (2019) Nanofibers as New-Generation Materials: From Spinning and Nano-Spinning Fabrication Techniques to Emerging Applications, Appl.Mater. Today. 17:1–35. https://doi.org/10.1016/j.apmt.2019.06.015
  14. Li W., Peng J., Li H., Wu Z., Huang Y., Chang B., et al. (2021) Encapsulating Nanoscale Silicon inside Carbon Fiber as Flexible Self-Supporting Anode Material for Lithium-Ion Battery, ACS Appl Energy Mater. 4:8529–37. https://doi.org/10.1021/acsaem.1c01713
  15. Monfared M., Taghizadeh S., Zare-Hoseinabadi A., Mousavi S.M., Hashemi S.A., Ranjbar S., et al. (2019) Emerging frontiers in drug release control by core-shell nanofibers: a review, Drug Metab. Rev. 51:589–611. https://doi.org/10.1080/03602532.2019.1642912
  16. Hu X., Liu S., Zhou G., Huang Y., Xie Z., Jing X., (2014) Electrospinning of polymeric nanofibers for drug delivery applications, J. Controlled Release. 185:12–21 https://doi.org/10.1016/j.jconrel.2014.04.018
  17. Zamani M., Prabhakaran M.P., Ramakrishna S., (2013) Advances in drug delivery via electrospun and electrosprayed nanomaterials, Int. J. Nanomed. 2997. https://doi.org/10.2147%2FIJN.S43575
  18. Valenta C., Auner B.G., (2004) The use of polymers for dermal and transdermal delivery, Eur. J. Pharm. Biopharm. 58:279–89. https://doi.org/10.1016/j.ejpb.2004.02.017
  19. Mali A., Bathe R.S., Patil M., (2015) An updated review on transdermal drug delivery systems, International Journal of Advances in Scientific Research. 1:244. http://dx.doi.org/10.7439/ijasr.v1i6.2243
  20. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., et al. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease. European journal of neurology. 13:1186–202. https://doi.org/10.1111/j.1468-1331.2006.01548.x
  21. Lieberman A., Ranhosky A., Korts D., (1997) Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 49:162–8. https://doi.org/10.1212/wnl.49.1.162
  22. Connolly B.S., Lang A.E., (2014) Pharmacological treatment of Parkinson disease: a review. Jama. 311:1670. https://doi.org/10.1001/jama.2014.3654
  23. Fawal G.E., Hong H., Song X., Wu J., Sun M., et al. (2020) Polyvinyl alcohol/hydroxyethylcellulose containing ethosomes as a scaffold for transdermal drug delivery applications. Appl. Biochem. Biotechnol. 191:1624–37. https://doi.org/10.1007/s12010-020-03282-1
  24. Sa’adon S., Razak S.I.A., Ismail A.E., Fakhruddin K., (2019) Drug-loaded poly-vinyl alcohol electrospun nanofibers for transdermal drug delivery: Review on factors affecting the drug release. Procedia Comput. Sci. 158:436–42. https://doi.org/10.1016/j.procs.2019.09.073
  25. Sebe I., Bodai Z., Eke Z., Kállai-Szabó B., Szabó P., Zelkó R., (2015) Comparison of directly compressed vitamin B12 tablets pre-pared from micronized rotary-spun microfibers and cast films. Drug Dev. Ind. Pharm. 41:1438–42. https://doi.org/10.3109/03639045.2014.956112
  26. Thenmozhi S., Dharmaraj N., Kadirvelu K., Kim H.Y., (2017) Electrospun nanofibers: New generation materials for advanced applications. Mater. Sci. Eng. B. 217:36–48. https://doi.org/10.1016/j.mseb.2017.01.001
  27. Wang C., Ma C., Wu Z., Liang H., Yan P., Song J., Ma N., Zhao Q., (2015) Enhanced Bioavailability and Anticancer Effect of Curcumin-Loaded Electrospun Nanofiber: In Vitro and in Vivo Study. Nanoscale Res. Lett. 10. https://doi.org/10.1186/s11671-015-1146-2
  28. Yu D.G., Zhang X.F., Shen X.X., Brandford-White C., Zhu L.M., (2009) Ultrafine ibuprofen-loaded polyvinyl pyrrolidone fiber mats using electrospinning. Polym. Int. 58:1010–3. https://doi.org/10.1002/pi.2629
  29. Huang L.Y., Branford-White C., Shen X.X., Yu D.G., Zhu L.M., (2012) Time-engineeringed biphasic drug release by electrospun nanofiber meshes. Int. J. Pharm. 436:88–96. https://doi.org/10.1016/j.ijpharm.2012.06.058
  30. Rahmani F., Ziyadi H., Baghali M., Luo H., Ramakrishna S., (2021) Electrospun PVP/PVA Nanofiber Mat as a Novel Potential Transdermal Drug-Delivery System for Buprenorphine: A Solution Needed for Pain Management, Appl. Sci. 11:2779. https://doi.org/10.3390/app11062779
  31. Zahra, F., Zhang, Y., Ajayi, A., Quick, Q., & Mu, R. (2024). Optimization of Electrospinning Parameters for Lower Molecular Weight Polymers: A Case Study on Polyvinylpyrrolidone. Polymers, 16. https://doi.org/10.3390/polym16091217.
  32. Tipduangta, P., Belton, P., Fábián, L., Wang, L., Tang, H., Eddleston, M., & Qi, S. (2016). Electrospun Polymer Blend Nanofibers for Tunable Drug Delivery: The Role of Transformative Phase Separation on Controlling the Release Rate.. Molecular pharmaceutics, 13 1, 25-39 . https://doi.org/10.1021/acs.molpharmaceut.5b00359.
  33. Kiaka, J., Moloto, M., & More, D. (2025). Effect of Cellulose Acetate on the Physicochemical Properties of PVP Blended Nanofibers. Current Nanomaterials. https://doi.org/10.2174/0124054615358729250716131528.
  34. Voikar V., Stanford S.C., (2021) The Open Field Test. In book: Psychiatric Vulnerability, Mood, and Anxiety Disorders, Tests and Models in Mice and Rats. http://dx.doi.org/10.1007/978-1-0716-2748-8_2 p. 9–29.
  35. Chen Y., Zhang Y., Li L., Holscher C., (2015) Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease. Eur J Pharmacol. 768:21–7. https://doi.org/10.1016/j.ejphar.2015.09.029
  36. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S.C., (2001) Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects, Neuropsychopharmacology. 25:633–41. http://dx.doi.org/10.1016/S0893-133X(01)00261-5.
  37. Bancroft J.D., Gamble M., Theory and practice of histological techniques. 6th Edition, Churchill Livingstone, Elsevier, China. 2008
  38. Singh B., Garg T., Goyal A.K., Rath G., (2016) Development, optimization, and characterization of polymeric electrospun nanofiber: A new attempt in sublingual delivery of nicorandil for the management of angina pectoris. Artif. Cells Nanomed. Biotechnol. 44:1498–507. https://doi.org/10.3109/21691401.2015.1052472.
  39. Ramakrishna S., Fujihara K., Teo W.E., Lim T.C., Ma Z., An Introduction to Electrospinning and Nanofibers; World Scientific Publishing Co.: Hackensack, NJ, USA. 2005
  40. Chien, Y., Ho, M., Feng, C., Yen, J., Chang, Y., Lai, C., & Louh, R. (2023). Fabrication of Glutaraldehyde Vapor Treated PVA/SA/GO/ZnO Electrospun Nanofibers with High Liquid Absorbability for Antimicrobial of Staphylococcus aureus. Nanomaterials, 13. https://doi.org/10.3390/nano13050932.
  41. Ullah, S., Hashmi, M., Hussain, N., Ullah, A., Sarwar, M., Saito, Y., Kim, S., & Kim, I. (2020). Stabilized nanofibers of polyvinyl alcohol (PVA) crosslinked by unique method for efficient removal of heavy metal ions. Journal of water process engineering, 33, 101111. https://doi.org/10.1016/j.jwpe.2019.101111.
  42. Zhang C., Zhai T., Turng L.S., (2018) Electrospinning of poly(lactic acid)/polycaprolactone blends: Investigation of the governing parameters and biocompatibility. J. Polym. Eng. 38:409–17. https://doi.org/10.1515/polyeng-2017-0194
  43. Ting-Yun K., Che-Min L., Shih-Chieh H., Tzu-Yang H., Da-Ming W., Hsyue-Jen H., (2018) Incorporation and selective removal of space-forming nanofibers to enhance the permeability of cytocompatible nanofiber membranes for better cell growth, Journal of the Taiwan Institute of Chemical Engineers. 91:146–54. https://doi.org/10.1016/j.jtice.2018.06.011
  44. Doğan E. E., Tokcan P., Diken M. E., Yilmaz B., Kizilduman B. K., Sabaz P., (2019) SYNTHESIS, CHARACTERIZATION AND SOME BIOLOGICAL PROPERTIES OF PVA/PVP/PN HYDROGEL NANOCOMPOSITES: ANTIBACTERIAL AND BIOCOMPATIBILITY, ADVANCES IN MATERIALS SCIENCE. 19: 32-45. Doi: 10.2478/adms-2019-0015
  45. Rahmani F., Ziyadi H., Baghali M., Luo H., Ramakrishna S., Electrospun PVP/PVA Nanofiber Mat as a Novel Potential Transdermal Drug-Delivery System for Buprenorphine: A Solution Needed for Pain Management., (2021) Applied Sciences. 11:2779. https://doi.org/10.3390/app11062779
  46. Anjum S., Li T., Arya D., Ali D., Alarifi S., Yulin W., Zhang H., Rajinikanth P., Ao Q. (2023) Biomimetic electrospun nanofibrous scaffold for tissue engineering: preparation, optimization by design of experiments (DOE), in-vitro and in-vivo characterization. Frontiers in Bioengineering and Biotechnology, 11. https://doi.org/10.3389/fbioe.2023.1288539.
  47. Rathore K., Singh I., Balani K., Sharma S., Verma V., (2024) Fabrication and characterization of multi-layered coaxial agar-based electrospun biocomposite mat, novel replacement for transdermal patches.. International journal of biological macromolecules, 133712. https://doi.org/10.1016/j.ijbiomac.2024.133712.
  48. Jiang Z., Zheng Z., Yu S., Gao Y., Ma J., Huang L., Yang L., (2023). Nanofiber Scaffolds as Drug Delivery Systems Promoting Wound Healing. Pharmaceutics, 15: 1829. https://doi.org/10.3390/pharmaceutics15071829.
  49. Castkova K., Kastyl J., Sobola D., Petrus J., Stastna E., et al. (2020) Structure–Properties Relationship of Electrospun PVDF Fibers, Nanomaterials (Basel). 10:1221. https://doi.org/10.3390/nano10061221
  50. Wang Y., Yu DG., Liu Y., Liu Y.N., (2022) Progress of Electrospun Nanofibrous Carriers for Modifications to Drug Release Profiles. J Funct Biomater. 13:289. doi: 10.3390/jfb13040289.
  51. Yekrang J., Gholam Shahbazi N., Rostami F., Ramyar M., (2023) A novel transdermal delivery route for energy supplements: Electrospun chitosan/polyvinyl alcohol nanofiber patches loaded with vitamin B12, International Journal of Biological Macromolecules. 230: 123187. doi: 10.1016/j.ijbiomac.2023.123187.
  52. Kamsani N.H., Hasan M.S., Rullah K., Haris M.S., (2024) Nicotine-Loaded Polyvinyl Alcohol Electrospun Nanofibers as Transdermal Patches for Smoking Cessation: Formulation and Characterization. Pharm Chem J. 57:1637–1646. https://doi.org/10.1007/s11094-024-03059-4
  53. Shaikh R.P., Kumar P., Choonara Y.E., du Toit L.C., Pillay V., (2012) Crosslinked electrospun PVA nanofibrous membranes: elucidation of their physicochemical, physicomechanical and molecular disposition. Biofabrication. 4:025002. doi: 10.1088/1758-5082/4/2/025002.
  54. Visser Z., Verma S., Rainey J., Frampton J., (2022). Loading and Release of Quercetin from Contact-Drawn Polyvinyl Alcohol Fiber Scaffolds. ACS pharmacology & translational science, 5:1305-1317. https://doi.org/10.1021/acsptsci.2c00191.
  55. Cui Z., Zheng Z., Lin L., Si J., Wang Q., Peng X., Chen W., (2018) Electrospinning and crosslinking of polyvinyl alcohol/chitosan composite nanofiber for transdermal drug delivery. Advances in Polymer Technology, 37:1917-1928. https://doi.org/10.1002/adv.21850.
  56. Wang Y., Yu D.G., Liu Y., Liu Y.N., (2022) Progress of Electrospun Nanofibrous Carriers for Modifications to Drug Release Profiles. J. Funct. Biomater. 13: 289. https://doi.org/10.3390/jfb13040289
  57. Mehrali F., Ziyadi H., Hekmati M., Faridi-Majidi R., Qomi M., (2023) Electrospun kefiran biocomposite nanofibers as a novel transdermal carrier of pramipexole. Nanomedicine Research Journal. 8: 193-209. https://doi.org/10.22034/nmrj.2023.02.009
  58. Moghaddami, F., Yekrang, J. & Dogolsar, M.A. (PVA/gelatin)–(PVA/chitosan) core-sheath nanofibers as promising route for transdermal delivery of folic acid: effect of fiber morphology, folic acid dosage, and loading location on release kinetics. (2025) emergent mater. https://doi.org/10.1007/s42247-025-01205-6
  59. Ren Q., Ma M., Yang J., Nonaka R., Yamaguchi A., et al. (2018) Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson’s disease. Proc Natl Acad Sci USA. 115. https://doi.org/10.1073/pnas.1802179115
  60. Rekha K.R., Selvakumar G.P., (2014) Gene expression regulation of Bcl2, Bax and cytochrome-C by geraniol on chronic MPTP/probenecid induced C57BL/6 mice model of Parkinson’s disease, Chem Biol Interact. 217:57–66 https://doi.org/10.1016/j.cbi.2014.04.010
  61. Wrangel C.V., Schwabe K., John N., Krauss J.K., Alam M., (2015) The rotenone-induced rat model of Parkinson’s disease: behavioral and electrophysiological findings. Behav Brain Res. 279:52–61. https://doi.org/10.1016/j.bbr.2014.11.002
  62. Balsara J., Jadhav J., Chandorkar A., (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy, Psychopharmacology (Berl). 62:67–9. http://dx.doi.org/10.1007/ BF00426037
  63. Oltval Z.N., Milliman C.L., Korsmeyer S.J., (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–19. https://doi.org/10.1016/0092-8674(93)90509-o
  64. Teema A.M., Zaitone S.A., Moustafa Y.M., (2016) Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis. Neuropharmacology. 107:432–50. https://doi.org/10.1016/j.neuropharm.2016.03.034
  65. Ren Z.I., Wang C.D., Wang T., Ding H., Zhou M., Yang N., et al. (2019) Ganoderma lucidum extract ameliorates MPTP-induced parkinsonism and protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis. Acta pharmacologica Sinica. 40:441–50. https://doi.org/10.1038/s41401-018-0077-8
  66. Singh P., Hanson P.S., Morris C.M., (2017) SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease. BMC neuroscience. 18. https://doi.org/10.1186/s12868-017-0364-1
  67. Dinis-Oliveira R.J., Remiao F., Carmo H., Duarte J.A., Navarro A.S., et al. (2006) Paraquat exposure as an etiological factor of Parkinson's disease. Neurotoxicology. https://doi.org/10.1016/j.neuro.2006.05.012 27:1110–22.
  68. Di Monte D.A., (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2:531–8. https://doi.org/10.1016/s1474-4422(03)00501-5
  69. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., et al. (2002) Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 10:119–27. https://doi.org/10.1006/nbdi.2002.0507
  70. Vanacore N., Nappo A., Gentile M., Brustolin A., Palange S., et al. (2002) Evaluation of risk of Parkinson's disease in a cohort of licensed pesticide users. Neurol Sci. 23: s119–20. https://doi.org/10.1007/s100720200098
  71. McCormack A.L., Atienza J.G., Johnston L.C., Andersen J.K., Vu S., Di Monte D.A., (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem. 93:1030–7. https://doi.org/10.1111/j.1471-4159.2005.03088.x
  72. Dauer W., Przedborski S., (2003) Parkinson's disease: mechanisms and models. Neuron. 39:889–909. https://doi.org/10.1016/s0896-6273(03)00568-3
  73. Uttara B., Singh A.V., Zamboni P., Mahajan R.T., (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 7:65–74. https://doi.org/10.2174%2F157015909787602823
  74. Schramm A., Matusik P., Osmenda G., Guzik T.J., (2012) Targeting NADPH oxidases in vascular pharmacology. Vasc Pharmacol. 56:216–31. https://doi.org/10.1016/j.vph.2012.02.012
  75. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., et al. (2002) Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis. 10:119–27. https://doi.org/10.1006/nbdi.2002.0507
  76. Wang Y., Yu X., Zhang P., Ma Y., Wang L., Xu H., Sui D., (2018) Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease. Journal of pharmacological sciences. 138:31–7. https://doi.org/10.1016/j.jphs.2018.08.008
  77. Abou-Sleiman P.M., Muqit M.M., Wood N.W., (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci. 7:207–19. https://doi.org/10.1038/nrn1868
  78. Henchcliffe C., Beal M.F., (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 4:600–9. https://doi.org/10.1038/ncpneuro0924
  79. Li Y., Liu W., Li L., Holscher C., (2016) Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology. 101:255–63. https://doi.org/10.1016/j.neuropharm.2015.10.002
  80. Li C., Tang B., Feng Y., et al. (2018) Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson's disease models through Nrf2 induction. J Agric Food Chem. 66:8307–18. https://doi.org/10.1021/acs.jafc.8b02607
  81. Czabotar P.E., Lessene G., Strasser A., et al. (2014) Control of apoptosis by the Bcl-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. https://doi.org/10.1038/nrm3722
  82. Eleawa S.M., Alkhateeb M.A., Alhashem F.H., et al. (2014) Resveratrol reverses cadmium chloride-induced testicular damage and subfertility by downregulating p53 and Bax and upregulating gonadotropins and Bcl-2 gene expression. J Reprod Dev. 60:115–27.https://doi.org/10.1262/jrd.2013-097
  83. Mitra S., Chakrabarti N., Bhattacharyya A., (2011) Differential regional expression patterns of α-synuclein, TNF-α, and IL-1β; and variable status of dopaminergic neurotoxicity in mouse brain after Paraquat treatment. Journal of neuroinflammation. 8.https://doi.org/10.1186/1742-2094-8-163.
  84. Farbood Y., Sarkaki A., Dolatshahi M., Mansouri S.M.T., Khodadadi A., (2015) Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson. 6:83-88.